pISSN 2234-3806eISSN 2234-3814
Table. 5.
Pharmacogenetic tests covered in the Korean healthcare reimbursement system
| Sector | EDI code | Method name | Gene name |
|---|---|---|---|
| HLA typing | D8413 | Nucleic acid amplification | HLA-B |
| D8414 | Sequencing | HLA-B |
|
| Hereditary genetic tests | C5801 | PCR-hybridization | CYP2C9 |
| MTHFR |
|||
| TPMT | |||
| VKORC1 | |||
| CYP2C19 | |||
| NUDT15 | |||
| C1581 | PCR-hybridization (multiple genes) | CYP2C9, VKORC1 | |
| C5802 | PCR-restriction fragment length polymorphism | MTHFR |
|
| C5806 | Sequencing (≤ 10 reactions) | CYP2C9 | |
| CYP2C19 | |||
| TPMT | |||
| UGT1A1 | |||
| VKORC1 | |||
| NUDT15 | |||
| C5807 | Sequencing (10 < reactions ≤ 20) | UGT1A1 | |
| CYP2C9 | |||
| CYP2C19 | |||
| CYP2D6 | |||
| TPMT | |||
| C5808 | Sequencing (20| G6PD |
| |
| C5809 | Sequencing (40| CFTR |
|
*MTHFR testing is only reimbursable for diagnostic investigations in patients with homocysteinemia (methylenetetrahydrofolate reductase deficiency), not for pharmacogenetic investigations in patients undergoing methotrexate treatment. Sequencing tests for CYP2C9, CYP2C19, TPMT, and UGT1A1 are divided into two groups based on the number of sequencing reactions: those with ≤10 reactions and those with >10 but <20 reactions.
Abbreviation: EDI, electronic data exchange.
Ann Lab Med 2025;45:121~132 https://doi.org/10.3343/alm.2024.0572
© Ann Lab Med